麝香通心滴丸联合常规西药治疗冠心病稳定型心绞痛临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:


Clinical Study on Shexiang Tongxin Dropping Pills Combined with Routine Western Medicine for Stable Angina Pectoris of Coronary Heart Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察麝香通心滴丸联合常规西药治疗冠心病稳定型心绞痛(SAP) 的临床疗效。方法:选取108 例冠心病SAP 患者,按简单随机化法分为研究组和对照组各54 例。对照组给予常规西药治疗,研究组在对照组的基础上加用麝香通心滴丸治疗。2 组均以1 周为1 个疗程,共治疗4 个疗程。评估2 组临床疗效、心绞痛发作改善情况及血脂水平。结果:治疗后,研究组总有效率为94.44%,对照组为72.22%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组中医证候积分比较,差异无统计学意义(P>0.05);治疗后,2 组中医证候积分均较治疗前降低,且研究组中医证候积分低于对照组(P<0.05)。治疗前,2 组心绞痛发作次数、心绞痛持续时间及ST 压低值比较,差异无统计学意义(P>0.05);治疗后,2 组心绞痛发作次数、发作持续时间及ST 段压低值均较治疗前减少(P<0.05),且研究组上述指标改善均优于对照组(P<0.05)。治疗前,2 组胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C) 水平比较,差异无统计学意义(P>0.05);治疗后,2 组TC、LDL-C、TG 水平均较治疗前降低(P<0.05),HDL-C 水平较治疗前升高(P<0.05),且研究组上述指标改善较对照组更显著(P<0.05)。结论:麝香通心滴丸联合常规西药治疗冠心病SAP 患者疗效显著,可有效改善患者临床症状、心绞痛发作情况及血脂水平。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Shexiang Tongxin dropping pills combined with routine western medicine for stable angina pectoris(SAP) of coronary heart disease. Methods: A total of 108 cases of SAP patients with coronary heart disease were selected and divided into the study group and the control group according to the simple randomization method,with 54 cases in each group. The control group was treated with routine western medicine,and the study group was additionally treated with Shexiang Tongxin dropping pills based on the treatment of the control group. Both groups were treated for four courses, with one week being one course. The clinical effects, the improvement of angina attacks and the levels of blood lipid in the two groups were evaluated. Results:After treatment,the total effective rate was 94.44% in the study group and 72.22% in the control group, the difference being significant(P<0.05). Before treatment, there was no significant difference being found in the comparison of Chinese medicine syndrome scores(P>0.05). After treatment, Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment,and the score in the study group was lower than that in the control group(P<0.05). Before treatment,there was no significant difference being found in the comparison of frequency and duration of angina pectoris and ST segment depression values between the two groups(P>0.05). After treatment, frequency and duration of angina pectoris and ST segment depression value in the two groups were decreased when compared with those before treatment(P<0.05),and the above indexes in the study group were better than those in the control group(P<0.05). Before treatment, there was no significant difference being found in the comparison of levels of total cholesterol(TC), triglyceride(TG), low- density lipoprotein cholesterol(LDL- C) and high- density lipoprotein cholesterol(HDL- C) between the two groups(P>0.05). After treatment,the levels of TC,LDL- C and TG in the two groups were lower than those before treatment(P<0.05),and the level of HDL- C was higher than that before treatment(P<0.05),the improvement of the above indexes in the study group was more significant than that in the control group(P<0.05). Conclusion: Shexiang Tongxin dropping pills combined with routine western medicine has a significant curative effect in treating patients with SAP of coronary heart disease, and can effectively improve their clinical symptoms,angina attacks and levels of blood lipid.

    参考文献
    相似文献
    引证文献
引用本文

夏海江.麝香通心滴丸联合常规西药治疗冠心病稳定型心绞痛临床研究[J].新中医,2022,54(8):64-67

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-04-24
  • 出版日期: